PHLDB2

Across TCGA pan-cancer cohorts, PHLDB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PHLDB2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PHLDB2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PHLDB2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

SKCM, UCEC, and THCA are the cancer types where PHLDB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.610	0.201	<.001	19	view →
UCEC	DFS	Median	II,III,IV	0.889	0.301	.009	16	view →
THCA	OS	Median	All	0.323	0.955	<.001	8	view →
BLCA	DFS	Median	II,III,IV	0.763	0.493	.028	6	view →
SCLC	DFS	Median	III,IV	1.000	0.229	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PHLDB2–SKCM (DFS)

Open the SKCM breakdown →